Indefinite delivery indefinite quantity (IDIQ) for the procurement of nilotinib tablets in support of the U.S. Department of health and human services (DHHS), national institutes of health (NIH),…
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N91023D00005
- Awardee
-
Regimed Medical UEI M2AHN6XHZFZ5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 5 $3,877,990 obligated
Award facts
- Opportunity
-
- Acquisition of Nilotinib (Tasigna®) Capsules, or Equivalent Solicitation · 75N91023Q00019 · Posted Dec 21, 2022
- Combined order value
- $3,877,990 Current and potential, with all options
- Last date to order 90% complete
- IDV ceiling 61% used
- $6,340,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- Total Small Business
- Competition
- Competed under SAP · 3 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded a Total Small Business set-aside Indefinite Delivery Contract to Regimed Medical on March 27, 2023, with a ceiling of $6.34 million and ultimate completion on March 26, 2027. This is a single-award IDIQ.
Regimed Medical is a minority-owned, Black American-owned small disadvantaged business based in O'Fallon, Missouri. Place of performance includes O'Fallon and St. Peters, Missouri, and Frederick, Maryland.
The IDIQ procures nilotinib tablets and capsules in 150 milligram and 200 milligram strengths in support of the National Institutes of Health National Cancer Institute Division of Cancer Treatment and Diagnosis Cancer Therapy Evaluation Program. The solicitation was posted December 21, 2022, with a due date of January 6, 2023.
Under this IDIQ, Regimed Medical has issued four delivery orders: a $951 thousand order (March 2023) for 150 milligram and 200 milligram nilotinib capsules; a $780 thousand order (September 2023) for 150 milligram and 200 milligram nilotinib capsules; a $1.7 million order (November 2023) for 150 milligram and 200 milligram nilotinib tablets; and a $219 thousand order (March 2025) for 200 milligram nilotinib tablets. A fifth delivery order valued at $219,850 for TASIGNA capsules was issued July 10, 2025, with performance at Frederick, Maryland and completion targeted July 9, 2026.
Description
Indefinite delivery indefinite quantity (IDIQ) for the procurement of nilotinib tablets in support of the U.S. Department of health and human services (DHHS), national institutes of health (NIH), national cancer institute (NCI), division of cancer TR
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91023D00005?
75N91023D00005 was awarded to Regimed Medical by National Cancer Institute (National Institutes of Health) on March 27, 2023.
How much is contract 75N91023D00005 worth?
Orders under 75N91023D00005 have obligated $3,877,990. 75N91023D00005's own ceiling is $6,340,000.
How many orders have been placed under contract 75N91023D00005?
5 orders have been placed under 75N91023D00005, the latest on July 10, 2025.
Who can order from contract 75N91023D00005?
75N91023D00005 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N91023D00005 competed?
The extent of competition for 75N91023D00005 was competed under sap. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV